About
Boryung, originally involved in pharmaceutical wholesale, transitioned into pharmaceutical manufacturing in 1963. Instead of simply being a drug manufacturer, the company decided to invest in the development of essential medicines for patients. This strategic shift paved the way for sustained growth in the pharmaceutical industry. Notably, in March 2011, Boryung achieved a significant milestone by introducing "Kanarb," the first ARB (Angiotensin II Receptor Blocker) antihypertensive medication in South Korea. Looking ahead, in April 2022, Boryung is set to host the inaugural Care in Space (CIS) Challenge. This initiative demonstrates the company's commitment to exploring new horizons and aligns with its mission to become an indispensable contributor to human health in the era of space exploration. By embarking on this challenge, Boryung aims to discover fresh opportunities that can further its role in advancing human health, especially as technological advancements open up new frontie
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 1,203 investors are based in Seoul, Seoul-t'ukpyolsi, South Korea.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Seoul, South Korea
Contact Information
Find more investors like Boryung
Search Investors